PURPOSE: The aim of this study was to assess the pharmacokinetics, biodistribution and metabolism of [(18)F]EF3, a labelled 2-nitroimidazole hypoxia marker, in ten patients with head and neck cancer. METHODS: [(18)F]EF3 was administered intravenously (group 1, n=5, mean dose+/-SD: 324+/-108 MBq; group 2, n=5, mean dose+/-SD: 1,134+/-138 MBq) to patients (nine male, one female). Blood and urine samples and whole-body PET scans were obtained from 20 s to 4-6 h. Radioactivity was determined in several regions of interest. RESULTS: No serious adverse event was reported. [(18)F]EF3 concentration in blood exhibited a bi-exponential decline. [(18)F]EF3 was mainly eliminated in the urine. By 7 h 40 min after injection, 53+/-14% of the injected dose was collected in the urine. There was no significant difference between the low- and high-dose groups. A progressive accumulation occurred also in the colon, indicating a hepatobiliary excretion. Except in organs involved in the elimination of [(18)F]EF3, the tumour-to-organ ratio remained close to or below unity in muscle, lungs, heart and brain at various times after injection. In one patient, tumour hypoxia was observed with a tumour-to-blood ratio ranging from 1.4 to 1.9. Last, [(18)F]EF3 remained very stable after injection, with percentage of native tracer above 87% in the serum and 84% in the urine. CONCLUSION: Administration of [(18)F]EF3 in head and neck cancer patients is feasible and safe. Uptake and retention in tumour was observed, indicating the presence of hypoxia.
PURPOSE: The aim of this study was to assess the pharmacokinetics, biodistribution and metabolism of [(18)F]EF3, a labelled 2-nitroimidazolehypoxia marker, in ten patients with head and neck cancer. METHODS: [(18)F]EF3 was administered intravenously (group 1, n=5, mean dose+/-SD: 324+/-108 MBq; group 2, n=5, mean dose+/-SD: 1,134+/-138 MBq) to patients (nine male, one female). Blood and urine samples and whole-body PET scans were obtained from 20 s to 4-6 h. Radioactivity was determined in several regions of interest. RESULTS: No serious adverse event was reported. [(18)F]EF3 concentration in blood exhibited a bi-exponential decline. [(18)F]EF3 was mainly eliminated in the urine. By 7 h 40 min after injection, 53+/-14% of the injected dose was collected in the urine. There was no significant difference between the low- and high-dose groups. A progressive accumulation occurred also in the colon, indicating a hepatobiliary excretion. Except in organs involved in the elimination of [(18)F]EF3, the tumour-to-organ ratio remained close to or below unity in muscle, lungs, heart and brain at various times after injection. In one patient, tumour hypoxia was observed with a tumour-to-blood ratio ranging from 1.4 to 1.9. Last, [(18)F]EF3 remained very stable after injection, with percentage of native tracer above 87% in the serum and 84% in the urine. CONCLUSION: Administration of [(18)F]EF3 in head and neck cancerpatients is feasible and safe. Uptake and retention in tumour was observed, indicating the presence of hypoxia.
Authors: R A Gatenby; H B Kessler; J S Rosenblum; L R Coia; P J Moldofsky; W H Hartz; G J Broder Journal: Int J Radiat Oncol Biol Phys Date: 1988-05 Impact factor: 7.038
Authors: W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: Sydney M Evans; Kevin D Judy; Isolde Dunphy; W Timothy Jenkins; Wei-Ting Hwang; Peter T Nelson; Robert A Lustig; Kevin Jenkins; Deirdre P Magarelli; Stephen M Hahn; Ruth A Collins; M Sean Grady; Cameron J Koch Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst Journal: Cancer Res Date: 1996-03-01 Impact factor: 12.701
Authors: Beatrice M Seddon; Geoffrey S Payne; Laura Simmons; Ruth Ruddle; Rachel Grimshaw; Siew Tan; Alison Turner; Florence Raynaud; Gavin Halbert; Martin O Leach; Ian Judson; Paul Workman Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Cameron J Koch; Joshua S Scheuermann; Chaitanya Divgi; Kevin D Judy; Alexander V Kachur; Richard Freifelder; Janet S Reddin; Joel Karp; James B Stubbs; Stephen M Hahn; Jason Driesbaugh; Deborah Smith; Susan Prendergast; Sydney M Evans Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-29 Impact factor: 9.236
Authors: R P Mason; D Zhao; J Pacheco-Torres; W Cui; V D Kodibagkar; P K Gulaka; G Hao; P Thorpe; E W Hahn; P Peschke Journal: Q J Nucl Med Mol Imaging Date: 2010-06 Impact factor: 2.346
Authors: Malene Martini Clausen; Anders Elias Hansen; Michael Lundemann; Christian Hollensen; Tobias Pommer; Per Munck Af Rosenschöld; Annemarie Thuri Kristensen; Andreas Kjær; Fintan J McEvoy; Svend Aage Engelholm Journal: Radiat Oncol Date: 2014-10-16 Impact factor: 3.481
Authors: Alexandra Marie Mowday; Janine Naomi Copp; Sophie Philippa Syddall; Ludwig Jerome Dubois; Jingli Wang; Natasja Gabi Lieuwes; Rianne Biemans; Amir Ashoorzadeh; Maria Rosaria Abbattista; Elsie May Williams; Christopher Paul Guise; Philippe Lambin; David Francis Ackerley; Jeff Bruce Smaill; Jan Theys; Adam Vorn Patterson Journal: Theranostics Date: 2020-08-21 Impact factor: 11.556